Sign Out
Pregnancy: Risk summary: There is insufficient experience with vildagliptin in pregnant women. Vildagliptin was not teratogenic in either rats or rabbits. Vildagliptin should not be used during pregnancy unless the benefit to the mother outweighs the potential risk to the fetus.
Lactation: Risk summary: As it is not known whether vildagliptin is excreted in human milk, it should not be administered to breast-feeding women.
Females and males of reproductive potential: No studies on the effect on human fertility have been conducted for vildagliptin. Fertility studies have been performed in rats and doses up to 200 times the human dose and have revealed no evidence of impaired fertility or early embryonic development.
